Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 5 October 2026 - 13:55

Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 5 October 2026 - 9:30

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 10, Status: Authorised

Second HMA/EMA multi-stakeholder forum on EudraVigilance and signal detection, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 December 2026, 09:00 (CET) to 1 December 2026, 17:30 (CET)

Submitted by Anonymous (not verified) on 5 October 2026 - 7:36

Second HMA/EMA multi-stakeholder forum on EudraVigilance and signal detection, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 December 2026, 09:00 (CET) to 1 December 2026, 17:30 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More